IGFBPL1 Peptide-Centric Chimeric Antigen Receptor Autologous T Cells for Relapsed HLA-A*02 Neuroblastoma and Medulloblastoma |
Children’s Hospital of Philadelphia / John Maris, MD |
Reach Grants |
2024 |
Pennsylvania |
Exploring the Interplay of Microbiome, Bile Acids, Immune Reconstitution, and Clinical Outcomes Following Allogeneic Hematopoietic Transplantation in Pediatrics |
Memorial Sloan-Kettering Cancer Center / Oriana Miltiadous, MD |
Reach Grants |
2024 |
New York |
Translating sarcoma antigen-directed co-stimulatory NK cells to the clinic |
Baylor College of Medicine / Robin Parihar |
Reach Grants |
2024 |
Texas |
Translating sarcoma antigen-directed co-stimulatory NK cells to the clinic |
Baylor College of Medicine / Robin Parihar, MD/PhD |
Reach Grants |
2024 |
Texas |
Investigating the impact of osteosarcoma genetic lesions on bone differentiation |
Dana-Farber Cancer Institute / James Morrow, MD/PhD |
Young Investigator Grants |
2024 |
Massachusetts |
Utilizing chromatin directed inhibitors to regulate gene expression in Ewing sarcoma for therapeutic benefit |
University of North Carolina / Justin Sperlazza, MD/PhD |
Young Investigator Grants |
2024 |
North Carolina |
Targeting and imaging immunometabolic vulnerabilities in diffuse midline glioma |
The Regents of the University of California San Francisco / Pavithra Viswanath, PhD |
Innovation Grants |
2024 |
California |
Direct targeting of oncoprotein assembly using mimetic peptide interference |
Memorial Sloan-Kettering Cancer Center / Alex Kentsis, MD/PhD |
Innovation Grants |
2024 |
New York |
Development of CAR-T therapy for Ewing sarcoma using zebrafish in vivo models |
Children’s Hospital Los Angeles / James Amatruda, MD/PhD |
Innovation Grants |
2024 |
California |
The role of reactive gliosis in response to Immunotherapy in Diffuse Midline Glioma |
University of Florida / Christina von Roemeling, PhD |
Innovation Grants |
2024 |
Florida |